Thursday, April 19, 2012

Reuters: Regulatory News: Merck ordered to pay $321 mln in criminal Vioxx probe

Reuters: Regulatory News
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Merck ordered to pay $321 mln in criminal Vioxx probe
Apr 19th 2012, 20:15

April 19 | Thu Apr 19, 2012 4:15pm EDT

April 19 (Reuters) - A Boston federal judge on Thursday sentenced Merck & Co to pay a $321 million criminal fine for improperly marketing its Vioxx painkiller a decade ago.

The U.S. drugmaker pleaded guilty in recent months to having illegally promoted Vioxx for treatment of rheumatoid arthritis before it was approved for that use in 2002. The pill, approved in 1999 as a painkiller, was withdrawn from the market in 2004 after it was linked to risk of heart attack and stroke.

Federal prosecutors in Boston said Merck illegally promoted Vioxx for rheumatoid arthritis for three years, continuing to do so after being reprimanded in September 2001 by the U.S. Food and Drug Administration.

In a related settlement reached in November, Merck agreed to pay more than $600 million to the federal government, 43 states and the District of Columbia for a wider range of alleged improprieties. But it did not acknowledge any wrongdoing in the civil settlement.

The Department of Justice on Thursday said the settlement involved allegations that Merck made misleading statements about Vioxx's heart safety to boost sales of the medicine, and that it prematurely promoted the drug for rheumatoid arthritis.

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 comments:

Post a Comment

 
Great HTML Templates from easytemplates.com.